Skip to content
Clinical Trials – home
Therapeutic area

Nervous system disorders – page 112

  • 1 388 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Clinical trials in Nervous system disorders

1 388 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 388 clinical trials

Parkinson's disease

Not recruiting
Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:5,7-Dimethyl-N-((1R,4R)-4-(Pentyloxy)Cyclohexyl)Pyrazolo[1,5-A]Pyrimidine-3-Carboxamide
  • Sponsor:Bial R&D Investments S.A.
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Universitair Medisch Centrum Groningen

Tourette's disorder

Not recruiting
Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years
  • Substances:Ecopipam Hydrochloride
  • Sponsor:Emalex Biosciences Inc.
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Sugammadex
  • Sponsor:Region Hovedstaden
Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Timbetasin Acetate
  • Sponsor:Regentree LLC

Epilepsy

Not recruiting
Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Prax-628
  • Sponsor:Praxis Precision Medicines Inc.
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Adezunap
  • Sponsor:Apurano Pharmaceuticals GmbH
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mk-1942
  • Sponsor:Merck Sharp & Dohme LLC
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Cannabidiol
  • Sponsor:Azienda Ospedaliera Universitaria Meyer IRCCS
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Cladribine
  • Sponsor:María Luisa Martínez Ginés
Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:(4R)-1-[(5-Chloro-1H-1,2,4-Triazol-1-Yl)Methyl]-4-(3,4,5-Trifluorophenyl)-2-Pyrrolidinone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ganaxolone
  • Sponsor:Marinus Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.